Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $31.7600 (-1.26%) ($31.6600 - $31.7600) on Tue. Oct. 26, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.5% (three month average) | RSI | 58 | Latest Price | $31.7600(-1.26%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | TGTX declines -0.1% a week on average for past two weeks. | Market Behavior | Normal for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(69%) ARKG(65%) ARKK(61%) IBB(61%) IWO(60%) | Factors Impacting TGTX price | TGTX will decline at least -2.25% in a week (0% probabilities). VIXM(-48%) VXX(-39%) UUP(-19%) UNG(-6%) TLT(-2%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.25% (StdDev 4.5%) | Hourly BBV | 0.3 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $27.51(-13.38%) | Resistance Level | $32.34 | 5 Day Moving Average | $31.79(-0.09%) | 10 Day Moving Average | $32.32(-1.73%) | 20 Day Moving Average | $32.34(-1.79%) | To recent high | -13.4% | To recent low | 46.5% | Market Cap | $4.022b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |